News

BREMEN, Germany – May 14, 2013 -  MALDI (Matrix-Assisted Laser Desorption Ionization) imaging is a mass spectrometric imaging technique that allows the untargeted measurement of proteins, peptides, lipids, drugs and metabolites directly from tissue. MALDI imaging has been successfully applied in various research fields. A particular area of application is the histopathology research concerned with the definition of molecular phenotypes in cancer, like expression patterns that are associated with progression of cancer, or the discovery of novel proteins associated with metastasis.

Technological improvements in recent years have increased the acquisition speed and spatial resolution of MALDI imaging datasets, generating demand for software that can handle the massive amount of data and helps in the generation of biological knowledge.

SCiLS Lab is the software developed by SCiLS GmbH which allows the user-friendly statistical analysis of large MALDI imaging datasets. It features new concepts such as an edge-preserving spatial de-noising and spatial segmentation of datasets with virtually un-limited size. It also allows the comprehensive analysis of studies with many patients, including unsupervised clustering and supervised classification.

“Comprehensive statistical analysis of large MALDI imaging datasets is one of the major demands of our customers”, said Dr. Shannon Cornett, Applications Development Manager and expert for MALDI imaging at Bruker. “The SCiLS team has channeled their mathematical and statistical expertise into a software product that surpasses anything that is currently available on the market. It integrates perfectly with our own flexImaging™ software and will be an integral part of our complete MALDI imaging solution. Unquestionably, SCiLS Lab will set new standards for analyzing MALDI imaging data, and I am confident that our customers will see tremendous benefit from this exclusive collaboration as it improves their imaging workflow.”

Dr. Dennis Trede, Managing Director at SCiLS GmbH, added: “We are happy to collaborate with the market and technology leader in the field of MALDI imaging and to benefit from Bruker’s distribution channels. We believe our software can push MALDI imaging forward by enabling the analysis of large data sets with unprecedented ease of use for everyone.”

Dr. Ferdinand von Eggeling, Professor at the University Hospital in Jena, Germany and user of Bruker’s MALDI imaging equipment explains: “We use MALDI imaging for the molecular analysis of head and neck cancers. My lab has been beta-testing the SCiLS Lab software, and the SCiLS team has been very knowledgeable and responsive to our suggestions. This software will enable the analysis of complex tumor tissues and make results more descriptive and accessible. ”
 
About SCiLS
SCiLS GmbH is an R&D company located in Bremen, Germany. SCiLS develops and markets the SCiLS Lab software for analysis and interpretation of MALDI imaging mass spectrometry data. SCiLS GmbH closely cooperates with the Steinbeis Innovation Center "SCiLS Research", and SCiLS is carrying out research projects on the European level contributing with R&D innovations and serving as a core platform for 2D and 3D MALDI-imaging data. For more information, please visit www.scils.de.

About Bruker Corporation
Bruker Corporation (NASDAQ: BRKR) is a leading provider of high performance scientific instruments and solutions for molecular and materials research, as well as industrial, diagnostics and applied analysis. For more information, please visit www.bruker.com.

For Further Information:
Dr. Sören-Oliver Deininger
Bruker Daltonik GmbH, Bremen, Germany
T: +49-421-2205-403
E:  sod(at)bdal.de

Media Contact:
Vicky Lander
Director of Global Marketing Communications Services
T: +1-978-663-3660
E: vicky.lander(at)bdal.com

BERGISCH GLADBACH, Germany--(BUSINESS WIRE)--May. 7, 2013-- RI Research Instruments GmbH, a majority-owned subsidiary of Bruker Energy & Supercon Technologies, Inc. (BEST), today announced the award of an option valued at approximately $7.3 million, for an additional 120 superconducting radio-frequency (rf) cavities, on top of its on-going 300-cavity contract for the European XFEL, a new international research facility near Hamburg, Germany. DESY (Deutsches Elektronen-Synchrotron) is the majority shareholder of the European XFEL, and in charge of building and operating the accelerator facility.

Since the initial DESY contract award in September 2010, RI has built up sophisticated infrastructure such as class ISO4 clean rooms with high pressure ultra-pure water rinsing stations, annealing furnaces and chemical plants, all of which are needed to treat the XFEL superconducting cavities for achieving the goal of world record accelerating gradients and quality factors.

The proper functioning of this infrastructure was validated by "reference cavities", which were first treated in existing and qualified infrastructure at DESY, followed by a cold rf test at the research center. The treatment was then repeated using RI infrastructure and personnel. With the consecutive successful cold rf test of three RI cavities, all reaching accelerating gradients above 30 MV/m at quality factors above 1E10, the qualification phase for the RI infrastructure officially concluded in March 2013. The start of series cavity shipments under the original 24.9 million Euro contract from DESY is expected to begin in the second quarter of 2013.

After this qualification achievement, DESY exercised its option for ordering an additional 120 superconducting 9-cell cavities from RI. With these 120 additional cavities, RI is now contracted to deliver a total of 420 cavities for the European XFEL project, out of which 400 will be used in the accelerator while 20 are either reference cavities, or for quality assurance followed by dedicated high accelerating gradient studies. RI is now proceeding with full series production of the XFEL cavities, with the goal of delivering at a rate of four cavities per week through early 2015.

Dr. Michael Peiniger, Managing Director of RI Research Instruments, explained: "With this successful qualification, industry is now able to put into series production the very complex superconducting cavity preparation processes that were developed by the world’s leading research labs to enable accelerating gradients greater than 30 MV/m. RI is pleased to be a reliable industrial partner for the European XFEL project, and looks forward to working on large next-generation projects such as the European Spallation Source and the future International Linear Collider."

About RI Research Instruments and Bruker Energy & Supercon Technologies, Inc.:

RI Research Instruments GmbH (RI) is a world leader in the development and manufacturing of normal and superconducting rf cavities and systems, linear accelerators, as well as special products for physics and energy research, scientific, medical and industrial applications. RI products also include high-performance electron and ion sources, particle beamlines and diagnostics, research reactor subunits, as well as vacuum and cryogenic systems. BEST has operations in the US, the UK and Germany, and is a wholly-owned subsidiary of Bruker Corporation (NASDAQ: BRKR).

For more information, please visit: www.research-instruments.de or www.bruker-est.com

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130507005978/en/

Source: Bruker Energy & Supercon Technologies, Inc.
RI GmbH
Dr. Hanspeter Vogel
Managing Director
+49 (0)2204 7062 3513
Hanspeter.Vogel(at)research-instruments.de

SANTA BARBARA, California, April 29, 2013 – Bruker’s Nano Surfaces division announced today the expansion of its proprietary PeakForce Tapping™ technology to the Dimension Edge™ AFM platform. PeakForce Tapping is the enabling technology behind Bruker’s popular suite of proprietary imaging modes, including ScanAsyst®, which brings unprecedented ease of use to AFM operation. ScanAsyst guarantees highest imaging resolution in air and fluid without the need for optimizing operating parameters. In applications ranging from standard roughness measurements to the most advanced electrochemical investigations, its inclusion on the Dimension Edge platform, makes highest resolution imaging accessible to an even wider user base.    

“Our patented ScanAsyst mode automates image optimization greatly simplifying the user experience and extending the utility of AFM,” said David V. Rossi, Executive Vice President and General Manager of Bruker's AFM Business. “The underlying PeakForce Tapping technology extends high-resolution AFM imaging to more samples by applying a precisely controlled, extremely low force response curve at every pixel, protecting our user’s probes and samples. ScanAsyst makes this capability accessible to more users by automatically monitoring image quality and making the correct parameter adjustments to deliver the best possible results to our customers.”  

About PeakForce Tapping

Through precise measurement technology and force control algorithms PeakForce Tapping permits the use of reduced imaging forces, protecting both fragile probes and samples, and increasing image resolution. In PeakForce Tapping, a complete force-distance curve is obtained and the peak force controlled directly at every pixel in an image. The lateral forces exerted in contact mode are eliminated, as is the spatial averaging of the interaction inherent to TappingMode. Performance benefits include the ability to perform high-resolution imaging in fluid on fragile samples, such as DNA; the elimination of cantilever equilibration issues; and, when combined with the Dimension Edge EC accessory, the enabling of advanced electrochemical research on lithium batteries. The benefits of PeakForce Tapping are reflected in the more than 100 peer-reviewed publications to date, showing that the adoption rate of this Bruker exclusive technology in the AFM community surpasses even that of Bruker’s industry-standard TappingMode™. ScanAsyst automates PeakForce Tapping, eliminating the need to adjust feedback parameters, a step that often presents a daunting challenge for new and intermediate users. The result is highest quality, most accurate imaging, guaranteed for all AFM users.  

About Dimension Edge

The Dimension Edge AFM features a proprietary closed-loop and drift-compensated stage that allows the productivity, accuracy, and sample versatility advantages of a large-sample, closed-loop system to be combined with the acquisition of high-resolution images traditionally only achieved by small-sample, open-loop systems. With lower noise levels, the Dimension Edge AFM system permits collection of the finer details critical to proper material identification, while protecting fragile tips and samples, and diminishing tip artifacts.  

Media Contact:
Stephen Hopkins, Marketing Communications
Bruker Nano Surfaces Division
3400 East Britannia Drive, Suite 150, Tucson, AZ 85706
T: +1 (520) 741-1044 x1022
E: steve.hopkins@bruker-nano.com

BERLIN--(BUSINESS WIRE)--Apr. 29, 2013-- At the 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Bruker shows new capabilities of the MALDI Biotyper™ platform.

The MALDI Biotyper (MBT) is the market-leading system for microbial identification based on MALDI-TOF mass spectrometry. It is widely used in clinical microbiology, industrial microbiology, animal health and food safety and has become the broadly accepted laboratory standard for next generation microbial identification. While conventional biochemical testing takes time-consuming incubation after selection of the microbes from the culture plate, the MALDI Biotyper allows for an instantaneous identification of colonies from a plate. The MALDI Biotyper system covers a broad range of more than 4,600 microbial isolates from gram-negative bacteria, gram-positive bacteria, yeasts, multicellular fungi and mycobacteria. It is broadly applicable as a standard identification tool in various fields of microbiology. Microbial identification with the MALDI Biotyper is done using a proteomic fingerprint. This unique species-specific pattern is automatically compared with reference spectra in the MALDI Biotyper library. In addition, the MALDI Biotyper supports the Open Microbiology Concept which allows customers to generate their own database entries from regional isolates via a push-button storage in a customer-specific sub-library.

The new second edition of the MBT Mycobacteria Library adds another 140 isolates from 37 new species. The library is fully compatible with all standard cultivation media for mycobacteria, such as solid Löwenstein-Jensen medium or in liquid culture using the MGIT™ system from Becton Dickinson. With these added capabilities the MALDI Biotyper covers now more than 130 species of mycobacteria.

The new MALDI Biotyper Pilot™ accessory complements the satellite software to a complete, barcoded and paperless workflow. The MBT Pilot is used for light-guided manual target preparation using cross hairs to indicate the next position for preparation on the MALDI target. Barcoding of the MALDI target and the sample, along with multiple isolate support, ensure that the complete process is fully traceable.

The new MALDI Biotyper Galaxy™ performs a quality-controlled automated deposition of the MALDI matrix onto the target plate. After the preparation it scans the target positions and checks if each spot is optimally prepared for MALDI Biotyper measurements. The MBT Galaxy has a seamless integration into the MBT server coupled with on-board barcode reading and automated loading of the associated project work list. Both MBT Pilot and MBT Galaxy are scheduled to be commercially available in 2013.

The revolutionary MALDI-Biotyper-Spectrum-Beta-Lactamase™ workflow (MSBL™) enables users to perform patented functional beta-lactam antibiotic resistance testing for selected antibiotics on the MALDI Biotyper platform. The cleavage of beta-lactam antibiotics, like penicillins, 3rd generation cephalosporins or carbapenems by resistant bacteria leads to specific mass shifts of the cleaved products. Such mass shifts can be observed and monitored using the MALDI Biotyper, and automatically interpreted with the MSBL software module, which is also expected to be commercially availability later this year.

Dr. Wolfgang Pusch, Executive Vice President - Microbiology Business at Bruker Daltonics, explained: “At the 2013 ECCMID in Berlin, Bruker is again showcasing very significant developments to further improve and streamline the established MALDI Biotyper workflow. The MALDI Biotyper Pilot and MALDI Biotyper Galaxy automation accessories add further functionality for quality control and traceability and at the same time reduce the manual workload of the operators. The MSBL method is another major step ahead to apply the MALDI Biotyper platform also in the fields of hospital hygiene and epidemiology to get fast results concerning resistance of bacteria to selected antibiotics.”

Professor David Livermore, University of East Anglia, Norwich, UK, commented: “I am very excited about the potential to detect beta-lactamases - and maybe other resistances - as well as to identify microbes by MALDI-TOF mass spectrometry. Early information about resistance is very important to antibiotic stewardship.”

About the Bruker MALDI Biotyper

The dedicated MALDI Biotyper solution enables molecular identification, and taxonomical classification or dereplication of microorganisms like bacteria, yeasts and fungi. Classification and identification of microorganisms is achieved reliably and quickly using proteomic fingerprinting by high-throughput MALDI-TOF mass spectrometry. Applications include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product safety and quality control, as well as marine microbiology. The robust MALDI Biotyper method requires minimal sample preparation and offers low consumables cost. The MALDI Biotyper is available in a research-use-only version, or in an IVD-CE version according to EU directive EC/98/79 in various European countries. In the United States of America the MALDI Biotyper is available for research use only, and not for use in diagnostic procedures.

*MGIT is a trademark of Becton Dickinson.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130429005006/en/

Source: Bruker Corporation

For Further Information:
Dr. Wolfgang Pusch
Bruker Daltonik GmbH, Bremen, Germany
 +49-421-2205-270
wpu@bdal.de
or
Media Contact:
Vicky Lander
Director of Global Marketing Communications Services
+1-978-663-3660
vicky.lander@bdal.com

STUTTGART, Germany – April 24h, 2013 – At the international technology trade fair for wine, fruit, fruit juice and spirits, INTERVITIS INTERFRUCTA 2013, Bruker today announced the second release of its successful NMR WineScreener^TM. With this new release more than 110 parameters can be evaluated under push button automation, with targeted analysis of more than 50 quantification parameters, and up to 60 statistical parameters, covering properties such as geographical origin, grape variety and vintage year. With this further increase in the already large number of analytical parameters obtained in a single NMR measurement, the NMR WineScreener 2.0 offers low costs per sample and even lower costs per individual parameter. The WineScreener analysis is built on more than 5,000 wines that have been measured over the last 15 month.

For every compound measured, quantified variety-specific concentration distribution curves are available, providing additional quality parameters beyond the OIV (Organisation International du Vin, www.oiv.int) defined thresholds.

The revolutionary performance of the NMR WineScreener 2.0 has convinced Intervitis/Interfructa officials to award a 2013 innovation prize to this unique wine-analysis system. Worldwide grape variety models for red and white wines form the basis of the statistical analysis, supplemented by origin and vintage models that provide valuable analysis tools for the authentication of wine.

“At the CVUA Karlsruhe we are using the principles of NMR-based food investigations for official surveillance very successfully, as established for the WineScreener and other matrices like cosmetics and drugs,” commented Dr. Thomas Kuballa, responsible for NMR analysis at the Chemical and Veterinary Investigation Office Karlsruhe (www.ua-bw.de).

‘We are convinced that the NMR WineScreener 2.0 initiates a new era in food quality control and are working towards the accreditation of the system in coordination with government control agencies,” said Dr. Manfred Spraul, Bruker’s Director of Applied NMR development.

A specification sheet detailing the possible analysis results is available. The NMR-based wine-analysis is supported and offered by WineSpin Analytics (www.winespin-analytics.de) and Eurofins (www.eurofins.com).

The NMR WineScreener is the second NMR-based food quality control solution offered by Bruker on the same hard- and software platform as the NMR JuiceScreener^TM, which offers push-button fruit juice and puree analysis of 23 fruit types, based on more than 16,000 spectra acquired over 4 years.

Media Contact:
Dr. Thorsten Thiel
Director of Marketing Communications
Bruker Corporation
T: +49 (721) 5161 – 6500
E: thorsten.thiel@bruker.com